Kexing Biopharm’s Generic Paclitaxel (Albumin-bound) Approved in Uruguay

Article source：Kexing BiopharmOct 31,2025View： 606

Recently, Kexing Biopharm (stock code: 688136.SH) , in collaboration with Haichang Biotech, which that its Generic Paclitaxel for Injection (Albumin-bound) has received marketing authorization from the Ministry of Public Health (MSP) of Uruguay. This approval marks a key milestone in expanding access to oncology therapies across Latin America.

Uruguay, known for its EU-aligned pharmaceutical standards and strategic geographic position, serves as a regional logistics hub for the Latin American pharmaceutical industry. Recognized globally as a frontline treatment recommended by international oncology guidelines, Generic Paclitaxel (Albumin-bound) has demonstrated a favorable safety profile and strong clinical acceptance. The approval of Generic Paclitaxel (Albumin-bound) further supports Kexing’s strategy to strengthen its commercial footprint and regulatory presence across the region.

Kexing Biopharm will continue to advance its “Global Selection + Global Coverage” strategy, partnering with international collaborators to expand product registration and commercialization, and to deliver broader treatment access to patients worldwide.

About Kexing

Kexing Biopharm (Stock Code: 688136.SH) is a multinational biopharmaceutical enterprise that engages in the R&D, manufacture and sales of innovative medicines of distinct modalities including recombinant proteins, antibodies, and targeted delivery therapies.

Through building cutting-edge technology platforms to advance the development of novel targeted therapies and drug delivery systems, Kexing Biopharm strives to address unmet clinical needs in the areas of oncology, autoimmune and antiviral treatment, creating a significant and meaningful positive impact on patients' lives.

By adhering to the platform development model driven by the twin engines of “Innovation & Internationalization”, Kexing Biopharm is committed to becoming a world leader in high-quality biopharmaceuticals, improving the health of patients worldwide.